Urat1 inhibitor
AssigneeJ-Pharma Co., Ltd.
InventorsTsuyoshi Endo, Kunio Kobayashi, Hiroto Tanaka, Daisuke Saito, Masaharu Hirano, Hitoshi Endou, Naohiko Anzai
Life of this patent
Estimating the term…
Loading patent…
AssigneeJ-Pharma Co., Ltd.
InventorsTsuyoshi Endo, Kunio Kobayashi, Hiroto Tanaka, Daisuke Saito, Masaharu Hirano, Hitoshi Endou, Naohiko Anzai
Estimating the term…
Provided are a compound represented by the following Formula (III), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt or solvate thereof used as a therapeutic agent for gout or hyperuricemia. (In the Formula (III), R1a, R2a, R6a, and R7a represent a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, an alkoxy group having 1 to 8 carbon atoms, or a cyano group, R3a and R8a form a benzene ring or a 5-membered heteroaryl ring containing 1 to 3 heteroatoms, as a ring constituent element, selected from nitrogen atoms, oxygen atoms, and sulfur atoms together with two carbon atoms to which R3a and R8a are bonded, R4a and R5a form a benzene ring together with two carbon atoms to which R4a and R5a are bonded or represent any of the groups represented by R1a described above, Wa represents CR10a or N, and where, R10a represents any of the groups represented by R1a, Xa represents an oxygen atom or a sulfur atom, Ya represents an alkylene chain having 1 to 8 carbon atoms, and where, the alkylene chain may be substituted with an alkyl group having 1 to 8 carbon atoms and the alkylene chain may be a linear or branched alkylene chain, the branched alkylene chain may have a 3- to 7-membered ring formed by side chains bonded to carbon atoms which are the same as or different from each other, together with the carbon atoms to which the side chains are bonded and may have a double bond in the middle thereof, and Za represents CO2H.)
A compound represented by the following Formula (I), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt or solvate thereof:
A compound represented by the following Formula (I), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt or solvate thereof:
A compound represented by the following Formula (IV), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt or solvate thereof:
A compound selected from the following compounds, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt or solvate thereof:
A compound selected from the following compounds, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt or solvate thereof:
A compound selected from the following compounds, a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt or solvate thereof:
A method of screening a substance having a URAT1 inhibitory action, the method comprising:
Dependencies are inferred from the claim text.